AI Data Ownership in Pharma

Send us Fan MailWe explore how AI is transforming content generation in the pharmaceutical industry, particularly in marketing, sales, and medical engagements. While AI presents groundbreaking opportunities, it also raises critical challenges, notably concerning data ownership and compliance.A significant issue is the lack of clarity around ownership of input and output data, illustrated by legal disputes like The New York Times suing OpenAI. For pharma companies, the stakes are high due to stringent FDA regulations. Missteps in AI-generated promotional materials can lead to hefty fines and reputational damage.We discuss the importance of rigorous internal reviews (PRC and MLR) for sales and marketing teams to ensure compliance and accuracy. Medical Affairs must also prioritize precision in AI-generated content to avoid misinformation that could harm patients.AI holds immense potential, but navigating issues of data ownership, regulatory compliance, and accuracy is essential for pharma companies. Join us for more discussions on AI in pharma, and feel free to reach out with topics you'd like us to cover!Support the showwww.kulkarnilawfirm.com